» Articles » PMID: 29915156

Disposition of Methamphetamine and Major Metabolites in Mice: Role of Organic Cation Transporter 3 in Tissue-Selective Accumulation of -Hydroxymethamphetamine

Overview
Specialty Pharmacology
Date 2018 Jun 20
PMID 29915156
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Methamphetamine is one of the most widely abused illicit drugs. Although human intoxication and multiple tissue toxicities frequently occur in abusers, little is known about the distribution of methamphetamine or its primary metabolites, amphetamine and -hydroxymethamphetamine (-OHMA), to their sites of toxicity. This study determined the pharmacokinetics, tissue exposure, and partition ratios of methamphetamine and major metabolites in various mouse tissues and investigated the impact of organic cation transporter 3 (Oct3) following i.v. injection of methamphetamine to male and mice. Methamphetamine, amphetamine, and -OHMA were readily detectable in plasma with and mice displaying similar plasma pharmacokinetic profiles for all three analytes. In addition to kidney and liver, salivary glands highly accumulated methamphetamine, amphetamine, and -OHMA with total exposure 3.3- to 9.4-fold higher than plasma area under the concentration-time curve (AUC). Consistent with being an Oct3 substrate, -OHMA AUC in salivary glands is reduced by 50% in mice. -OHMA AUC in skeletal muscle is also significantly reduced in mice. Our data identified salivary glands as a novel site of high accumulation of methamphetamine and metabolites, which may underlie methamphetamine toxicity in this tissue. Furthermore, our study identified Oct3 as an important determinant of tissue uptake and exposure to -OHMA in salivary glands and skeletal muscle. Our findings suggest that local tissue accumulation of methamphetamine and/or its metabolites may play a role in several of the reported peripheral toxicities of methamphetamine, and Oct3 can significantly impact tissue exposure to its substrates without affecting systemic elimination.

Citing Articles

Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.

Khan R, Turner A, Berk M, Walder K, Rossell S, Guerin A Biomolecules. 2025; 15(2).

PMID: 40001609 PMC: 11852989. DOI: 10.3390/biom15020306.


Cardiac Uptake of the Adrenergic Imaging Agent -Iodobenzylguanidine (mIBG) Is Mediated by Organic Cation Transporter 3 (Oct3).

Quinones A, Vieira L, Wang J Drug Metab Dispos. 2024; 52(8):899-905.

PMID: 38811159 PMC: 11257688. DOI: 10.1124/dmd.124.001709.


Organic cation transporters in psychiatric and substance use disorders.

Honan L, Fraser-Spears R, Daws L Pharmacol Ther. 2023; 253:108574.

PMID: 38072333 PMC: 11052553. DOI: 10.1016/j.pharmthera.2023.108574.


.

Quinones A, Vieira L, Wang J Drug Metab Dispos. 2022; 50(9).

PMID: 35197314 PMC: 9488973. DOI: 10.1124/dmd.121.000707.


Methamphetamine enhances caveolar transport of therapeutic agents across the rodent blood-brain barrier.

Chang J, Greene C, Frudd K, Araujo Dos Santos L, Futter C, Nichols B Cell Rep Med. 2022; 3(1):100497.

PMID: 35106509 PMC: 8784794. DOI: 10.1016/j.xcrm.2021.100497.


References
1.
Cui M, Aras R, Christian W, Rappold P, Hatwar M, Panza J . The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A. 2009; 106(19):8043-8. PMC: 2683105. DOI: 10.1073/pnas.0900358106. View

2.
Gasser P, Orchinik M, Raju I, Lowry C . Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol. 2008; 512(4):529-55. DOI: 10.1002/cne.21921. View

3.
Mager H, Goller G . Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies. J Pharm Sci. 1998; 87(3):372-8. DOI: 10.1021/js970114h. View

4.
Ravenel M, Salinas C, Marlow N, Slate E, Evans Z, Miller P . Methamphetamine abuse and oral health: a pilot study of "meth mouth". Quintessence Int. 2012; 43(3):229-37. View

5.
de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S . Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004; 43(3):157-85. DOI: 10.2165/00003088-200443030-00002. View